The New England Journal of Medicine (NEJM) RSS feed -- Search Results in Allergy/Immunology. NEJM (https://www.nejm.org) is a weekly general medical journal that publishes new medical research findings, review articles, and editorial opinion on a wide variety of topics of importance to biomedical science and clinical practice. https://www.nejm.org/action/showPodcastsFeeds NEJM Group Wed, 03 Jun 2026 21:02:11 GMT 2026 NEJM Group en-us 1440 HLA sensitization poses major challenges to kidney transplantation. This report describes transplantation in two highly sensitized candidates after desensitization with dual CAR T-cell therapy. https://www.nejm.org/doi/full/10.1056/NEJMoa2513428?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2513428 Vijay G. Bhoj, Mary Kaminski, Huiwu Zhao, Kyle Jackson, Wei Wang, Chengyang Liu, Robert A. Montgomery, Nicole Ali, Massimo Mangiola, Thomas R. Spitzer, Kassem Safa, Vikram Pattanayak, Raeda Taj, Joy Chiu, Thanh-Mai Bui, Elizabeth M. Sonnenberg, James F. Markmann, Michael C. Milone, Carl H. June, Don L. Siegel, Joseph A. Fraietta, Vanessa Gonzalez, Michela Locci, Matthew Palmer, Dimitri Monos, Wei-Ting Hwang, Tina Sledge, Nancy D. Bridges, Julia S. Goldstein, Jonah Odim, Stuart C. Sweet, Behdad D. Besharatian, Sabiha M. Hussain, Nicholas K. Brown, Malek Kamoun, Alfred L. Garfall, Ali Naji 2026-06-04 Brief Report: Kidney Transplantation in Two Highly Sensitized Candidates after CAR T-Cell Therapy Vaccine hesitancy is often driven by safety concerns. Clinician recommendations, presumptive communication, and empathy improve uptake; maintaining trust supports future acceptance and community protection. https://www.nejm.org/doi/full/10.1056/NEJMcp2516616?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMcp2516616 Sean T. O’Leary, Margie Danchin 2026-06-04 Childhood Vaccine Hesitancy A 53-year-old man with Crohn’s disease and psoriasis presented with a 2-day history of headache, slurred speech, nausea, and vomiting. During the previous 2 weeks, he had had yellowing of the skin and eyes and dark urine. https://www.nejm.org/doi/full/10.1056/NEJMcps2506943?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMcps2506943 Brittany B. Bromfield, Nikroo Hashemi, Mark S. Redston, Katherine H. Walker, Bruce D. Levy 2026-06-04 The Unusual Suspects This letter reports the clinical course of a broadly HLA-sensitized patient in whom anti-CD19 CAR T-cell therapy enabled successful kidney transplantation. https://www.nejm.org/doi/full/10.1056/NEJMc2517277?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMc2517277 Jens Schrezenmeier, Hector Rincon-Arevalo, Nils Lachmann, Diana Stauch, Brigitta Globke, Robert Öllinger, Lukas J. Lehner, Stella Lesch, Gerhard Krönke, David Simon, Dominic Borie, Mira Choi, Frederik Damm, Mareike Frick, Philip F. Halloran, Klemens Budde, Brian J.P. Huntly, Lars Bullinger, Kai-Uwe Eckardt, Thomas Dörner, Olaf Penack, Fabian Halleck, Eva Schrezenmeier 2026-06-04 Kidney Transplantation after Clearing Anti-HLA Antibodies with CD19 CAR T Cells Among patients with relapsed polymyalgia rheumatica, treatment with secukinumab plus a 24-week glucocorticoid taper resulted in a higher percentage of patients with remission than a glucocorticoid taper alone. https://www.nejm.org/doi/full/10.1056/NEJMoa2602567?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2602567 John H. Stone, Frank Buttgereit, Alain Saraux, Wolfgang A. Schmidt, Christian Dejaco, Robert Spiera, Bhaskar Dasgupta, Edit Drescher, Andrew Jordan, Libor Novosad, Daiki Nakagomi, Yoshinobu Koyama, Sergio Duran-Barragan, Gerald Tracey, Adeline Ruyssen-Witrand, Andrea Rubbert Roth, Juanzhi Fang, Jennifer Ng, Renuka Hiremath, Roselyne Raffner, Ruvie Martin, Silvia Napoletano, Songqiao Huang, Julian Storim, Manmath Patekar, the REPLENISH Investigators* 2026-06-03 Phase 3 Trial of Secukinumab in Polymyalgia Rheumatica Since Dr. Phillip Hench reported on the efficacy of glucocorticoids for rheumatoid arthritis in 1949, glucocorticoids have saved many lives and have offered relief to countless patients. Glucocorticoids have been used as the mainstay of treatment for many immune-mediated inflammatory diseases, including polymyalgia rheumatica and giant-cell arteritis (GCA), owing to... https://www.nejm.org/doi/full/10.1056/NEJMe2605851?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMe2605851 Yoshiya Tanaka 2026-06-03 Emerging Era for Polymyalgia Rheumatica and GCA — Interleukin-17A Targeting In a phase 3 trial, obexelimab led to a lower risk of disease flares than placebo among patients with IgG4-related disease. Glucocorticoid use was lower and the incidence of remission was higher with obexelimab than with placebo. https://www.nejm.org/doi/full/10.1056/NEJMoa2601337?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2601337 Emanuel Della-Torre, Matthew C. Baker, Wen Zhang, Cory A. Perugino, Guy Katz, Yoshiya Tanaka, Arezou Khosroshahi, Alexander Kleger, Nicolas Schleinitz, Fernando Martinez-Valle, Hendrik Schulze-Koops, Shingo Nakayamada, Vinciane Rebours, Kazuichi Okazaki, Lingli Dong, Mollie Carruthers, Luke Y.C. Chen, Luca Frulloni, Alireza Meysami, Hiroki Takahashi, Mitsuhiro Kawano, Yanying Liu, Takako Saeki, Mikael Ebbo, Tobias Alexander, Andrés González García, Omer Karadag, Maria Maślińska, Shauna M. Quinn, Allen Poma, Audrey Wells, Thomas J. Greene, John H. Stone, Emma L. Culver, the INDIGO Trial Investigators* 2026-06-02 Obexelimab for the Treatment of IgG4-Related Disease IgG4-related disease has emerged as one of the clearest human models for understanding the role of B-lineage cells in immune-mediated inflammation. Although glucocorticoids remain effective for inducing remission, relapse during tapering is common, cumulative toxic effects are substantial, and durable disease control remains difficult to achieve. Della-Torre et al.1 https://www.nejm.org/doi/full/10.1056/NEJMe2605617?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMe2605617 Thomas Dörner 2026-06-02 Obexelimab and the Promise of Nondepleting B-Cell Therapy in IgG4-Related Disease A 64-year-old woman presented with fatigue, memory changes, and falls. MRI of the head revealed numerous hyperintense foci in the white matter on fluid-attenuated inversion recovery images. A diagnosis was made. https://www.nejm.org/doi/full/10.1056/NEJMcpc2517865?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMcpc2517865 Shamik Bhattacharyya, Samuel C.D. Cartmell, Albert Y. Hung, Philippe A. Bilodeau, Elizabeth C. Conner 2026-05-28 Case 15-2026: A 64-Year-Old Woman with Fatigue, Memory Changes, and Falls Two patients with inborn errors of immunity and progressive multifocal leukoencephalopathy received polyomavirus-specific T cells, followed by allogeneic hematopoietic transplantation with good neurologic outcomes. https://www.nejm.org/doi/full/10.1056/NEJMc2514186?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMc2514186 Corina E. Gonzalez, Anita Fletcher, Tonya L. Jenkins, Sara Zahraeifard, Rose Peterson, Milo Taylor, Christine Jones, Amanda Urban, Daniele Avila, Mauricio Campillay, Jamie Wilhelm, Ariane Soldatos, Jens Kuhle, Poorva Jain, Sydney Corey, Jenna R.E. Bergerson, Daniel S. Reich, Steven Highfill, David Stroncek, Anh Dinh, Stefania Pittaluga, Heidi H. Kong, Helen C. Su, Luigi D. Notarangelo, Sung-Yun Pai, Michael Grimley, Alexandra F. Freeman, Irene Cortese 2026-05-28 Resolution of PML after Treatment with Virus-Specific T Cells and HCT Azithromycin did not lead to a greater reduction in symptom severity than placebo among preschool children presenting to the emergency department with wheezing, regardless of whether they tested positive for pathogenic bacteria. https://www.nejm.org/doi/full/10.1056/NEJMoa2516505?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2516505 Kurt R. Denninghoff, T. Charles Casper, Joseph J. Zorc, Richard M. Ruddy, Sarah Satola, Wendi-Jo Wendt, Claudia R. Morris, Melissa M. Tavarez, Matthew J. Lipshaw, Maria Y. Kwok, Jo-Ann O. Nesiama, Kyle A. Nelson, Michael Webb, Fernando D. Martinez, the PECARN AZ-SWED Trial Study Group* 2026-05-18 Azithromycin for Preschoolers with Wheezing in the Emergency Department In a trial of brepocitinib in adults with dermatomyositis, the 30-mg dose (but not the 15-mg dose) led to greater improvement on a composite myositis index at 52 weeks than placebo. Serious infections were more frequent with the 30-mg dose. https://www.nejm.org/doi/full/10.1056/NEJMoa2503531?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2503531 Ruth Ann Vleugels, Julie J. Paik, Iazsmin Bauer Ventura, Aaron R. Mangold, Prateek C. Gandiga, Anna Haemel, Hector Chinoy, Yessar M. Hussain, Kumaraswamy Sivakumar, Zoltan Griger, Eun Bong Lee, Francisca Bozan, Chung-Yuan Hsu, Alisa Femia, Mazen M. Dimachkie, Michelle S. Min, Tahseen Mozaffar, Christina Charles-Schoeman, David R. Fernandez, Oluwakemi Onajin, Raquel Campanilho-Marques, Galina Marder, Floranne Ernste, Elena Schiopu, Jason Sluzevich, David Pearson, Stephen Lindsey, Michael Luggen, Michael R. Bubb, Erin Boh, Rashmi Maganti, Latisha Heinlen, Katharina S. Shaw, Matthew D. Cascino, Paul N. Mudd Jr., Jiri Vencovsky, Anthony P. Fernandez, David Fiorentino, Lisa Christopher-Stine, Victoria P. Werth, Rohit Aggarwal, the VALOR Investigators* 2026-05-14 A Phase 3 Trial of Brepocitinib in Dermatomyositis Inflammatory myopathies are typically associated with a myositis-specific autoantibody that determines the diagnosis and prognosis. Myositis subgroups have distinct pathomechanisms that now allow for targeted therapies. https://www.nejm.org/doi/full/10.1056/NEJMra2415426?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMra2415426 Yves Allenbach, Olivier Benveniste 2026-05-14 Inflammatory Myopathies Dermatomyositis is a subgroup of idiopathic inflammatory myopathies — systemic autoimmune disorders that are typically characterized by the involvement of multiple organs, including muscle, skin, joints, lungs, gastrointestinal tract, and heart — all conditions with high morbidity and mortality.1 Treatment of myositis is based on off-label use of... https://www.nejm.org/doi/full/10.1056/NEJMe2604009?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMe2604009 Ingrid E. Lundberg 2026-05-14 A Phase 3 Trial of Brepocitinib in Dermatomyositis A 50-year-old woman was admitted to the hospital because of vaginal bleeding and anemia. She had a history of fibroids and 1 month of progressive thrombocytopenia. A diagnosis was made. https://www.nejm.org/doi/full/10.1056/NEJMcpc2517864?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMcpc2517864 Joshua C. Ziperstein, Rashid A. Barnawi, Hanny Al-Samkari, Marcy B. Bolster, Lauren E. Heusinkveld 2026-05-14 Case 14-2026: A 50-Year-Old Woman with Vaginal Bleeding and Anemia Cerebral amyloid angiopathy, caused by beta-amyloid deposition in brain blood vessels, leads to lobar cerebral hemorrhage, microbleeds, and white-matter lesions and contributes to cognitive decline. https://www.nejm.org/doi/full/10.1056/NEJMra2411298?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMra2411298 Steven M. Greenberg 2026-05-07 Cerebral Amyloid Angiopathy An 86-year-old man presented to the neurology clinic with 2 years of progressive memory loss and difficulty walking. An MRI showed microbleeds that appeared as hypointense foci throughout the lobar regions. https://www.nejm.org/doi/full/10.1056/NEJMicm2511044?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMicm2511044 Sihui Chen, Xueping Chen 2026-05-07 Cerebral Amyloid Angiopathy The administration recently announced a new payment model to align some Medicare Part B drug payments with international pricing benchmarks. Various factors could affect the model’s scope and impact. https://www.nejm.org/doi/full/10.1056/NEJMp2600417?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMp2600417 Thomas J. Hwang, Lisa Clemans-Cope, Aaron S. Kesselheim 2026-05-07 Reforming Payment for Clinician-Administered Drugs — Most-Favored-Nation Pricing in Medicare Part B A 62-year-old man was admitted to the hospital for malaise, anorexia, rash, and diffuse lymphadenopathy. Fatigue and anorexia began 6 months earlier. Four months before admission, a pruritic rash developed on the back and spread. https://www.nejm.org/doi/full/10.1056/NEJMcps2511351?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMcps2511351 Masami Matsumura, Naoki Kanda, Shuji Hatakeyama, Gurpreet Dhaliwal 2026-05-07 Immune Interference In a randomized trial involving 3208 children with Kawasaki disease, adding prednisolone to standard primary therapy did not reduce the incidence of coronary-artery lesions at 1 month. https://www.nejm.org/doi/full/10.1056/NEJMoa2511478?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2511478 Siyuan Lin, Yuanchen He, Lan He, Yiling Liu, Fangjie Wang, Zhenyu Xiong, Yixiang Lin, Lan Ye, Chen Chu, Feng Wang, Lu Zhao, Yinyin Cao, Yuanzheng Zheng, Qin Huang, Jie Wang, Xuecun Liang, Quming Zhao, Shuna Sun, Yalan Dou, Wennan He, Xiaobi Huang, Jingwei Sun, Xianmei Huang, Yan Li, Yanling Liao, Haitao Lv, Silin Pan, Hua Zhu, Xinjiang An, Xuehua He, Cuifen Zhao, Xiaoyan Liu, Yaofei Hu, Jinhua Piao, Lijun Qin, Xiangyu Dong, Qian Peng, Ce Wang, Shubin Lin, Ping Huang, Rongzhou Wu, Hua Peng, Zipu Li, Duolao Wang, Xiaohui Liu, Weili Yan, Fang Liu, Guoying Huang, the Chinese Kawasaki Disease Collaboration Network* 2026-04-16 Randomized Trial of Adjunctive Prednisolone for Kawasaki Disease